| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/15/2006 | EP1633354A2 N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes |
| 03/15/2006 | EP1633353A1 Composition and method for treating macular disorders |
| 03/15/2006 | EP1633351A1 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 03/15/2006 | EP1633350A2 Acylated amino acid amidyl pyrazoles and related compounds |
| 03/15/2006 | EP1633346A1 Pyrrolidin-1, 2- dicarboxylic acid- 1- (4- ethinyl- phenyl) - amid]- 2- (phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis |
| 03/15/2006 | EP1633345A1 Compounds inhibiting the binding of sap for treating osteoarthritis |
| 03/15/2006 | EP1633344A2 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer's disease |
| 03/15/2006 | EP1633343A1 3-aminomethyl-pyrrolidines as n-type calcium channel blockers |
| 03/15/2006 | EP1633342A2 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions |
| 03/15/2006 | EP1633341A2 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis |
| 03/15/2006 | EP1633340A2 Compounds for the treatment of metabolic disorders |
| 03/15/2006 | EP1633339A1 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
| 03/15/2006 | EP1633338A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 03/15/2006 | EP1633337A2 Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers |
| 03/15/2006 | EP1633336A2 Immunosuppressant compounds and compositions |
| 03/15/2006 | EP1633335A1 Improved absorption of fat-soluble nutrients |
| 03/15/2006 | EP1633334A2 A method of promoting sleep using topical administration of vasoactive agents |
| 03/15/2006 | EP1633333A1 Use of hif alpha stabilizers for enhancing erythropoiesis |
| 03/15/2006 | EP1633329A1 Modified release formulations of selective serotonin re-uptake inhibitors |
| 03/15/2006 | EP1633328A1 Method and composition for stable and controlled delivery of (-)-hydroxycitric acid |
| 03/15/2006 | EP1633325A1 Oil emulsion for postnatal hormone substitution |
| 03/15/2006 | EP1633323A2 Ternary and quaternary eutectic mixtures |
| 03/15/2006 | EP1633322A2 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
| 03/15/2006 | EP1633320A2 Implantable controlled release bioactive agent delivery device |
| 03/15/2006 | EP1633311A2 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 03/15/2006 | EP1633306A2 Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders |
| 03/15/2006 | EP1633211A1 Hot liquid fiber product |
| 03/15/2006 | EP1633208A1 Novel nutraceutical compositions and use thereof |
| 03/15/2006 | EP1633193A1 Agents against microorganisms, containing patchouli oil, patchouli alcohol and/or the derivatives thereof |
| 03/15/2006 | EP1633189A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 03/15/2006 | EP1608634A4 Methods for isolating crystalline form i of 5-azacytidine |
| 03/15/2006 | EP1596842A4 Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| 03/15/2006 | EP1567151B1 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer |
| 03/15/2006 | EP1521595B1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 03/15/2006 | EP1513834B1 Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same |
| 03/15/2006 | EP1509530B1 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 03/15/2006 | EP1492797B1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof |
| 03/15/2006 | EP1465864B1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 03/15/2006 | EP1461040B1 Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| 03/15/2006 | EP1451577A4 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
| 03/15/2006 | EP1448566B1 Chemokine receptor antagonists and methods of use thereof |
| 03/15/2006 | EP1444206B1 Substituted benzo[b]azepin-2-one compounds as analgesics |
| 03/15/2006 | EP1438001A4 Compositions and methods for inhibiting eccrine perspiration in humans |
| 03/15/2006 | EP1435908A4 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 03/15/2006 | EP1408962B1 Substituted isoindoles and the use thereof |
| 03/15/2006 | EP1404303A4 Stable pharmaceutical compositions containing pravastatin |
| 03/15/2006 | EP1403249B1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 03/15/2006 | EP1401435B1 Topical application of thiazolyl amides |
| 03/15/2006 | EP1390039B1 Use of estrogen compounds to increase libido in women |
| 03/15/2006 | EP1383498B1 Crf receptor antagonists |
| 03/15/2006 | EP1372648B1 Tie2 receptor kinase inhibitors for treating angiogenic diseases |
| 03/15/2006 | EP1339414A4 L-histidine in ophthalmic solutions |
| 03/15/2006 | EP1331937B1 Dibenzoxazepine alpha v integrin receptor antagonist |
| 03/15/2006 | EP1326864B1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 03/15/2006 | EP1324749B1 Medicinal aerosol formulations |
| 03/15/2006 | EP1322156B1 Disinfectant |
| 03/15/2006 | EP1318819A4 Treatment of trauma, and other indications |
| 03/15/2006 | EP1309593B1 Substituted pyrazoles |
| 03/15/2006 | EP1309589B1 Urea compounds and methods of uses |
| 03/15/2006 | EP1296679B1 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 03/15/2006 | EP1289992B1 New crystalline form of a triazolo(4,5-d)pyrimidine compound |
| 03/15/2006 | EP1283713B1 Combined cartilage and plant extract compositions |
| 03/15/2006 | EP1263426B1 Preparations for the non-traumatic excision of a nail |
| 03/15/2006 | EP1254209B1 Composition comprising hydroxycitric acid and garcinol for weight-loss |
| 03/15/2006 | EP1250130A4 Propofol formulation with enhanced microbial inhibition |
| 03/15/2006 | EP1227085B1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 03/15/2006 | EP1196172B1 (S,S)-Reboxetine for treating chronic pain |
| 03/15/2006 | EP1140958B1 Anti-(retro)viral conjugates of saccharides and acetamidino or guanidino compounds |
| 03/15/2006 | EP1140044B1 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION |
| 03/15/2006 | EP1129078B1 Indazole derivatives with 5-ht2 receptor activity |
| 03/15/2006 | EP1117356B1 Apparatus for improved administration of fentanyl and sufentanil |
| 03/15/2006 | EP1115375B1 Use of at least a10-hydroxy-2- decenoic acid derivative in a composition for promoting skin scaling |
| 03/15/2006 | EP1094821B1 Sulfur-containing phosphonoformate derivatives and their uses. |
| 03/15/2006 | EP1063885B1 Xylitol compositions for treating upper respiratory conditions |
| 03/15/2006 | EP1028710A4 Topical compositions for nsai drug delivery |
| 03/15/2006 | EP1020446B1 Naphthalimidobenzamide derivatives |
| 03/15/2006 | EP0997147B1 Amino acid derivatives |
| 03/15/2006 | EP0934292B1 Metalloproteinase inhibitors |
| 03/15/2006 | EP0929554B1 Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists |
| 03/15/2006 | EP0870049B1 Complementary adenoviral vector systems and cell lines |
| 03/15/2006 | EP0804438B1 Tricyclic benzazepine vasopressin antagonists |
| 03/15/2006 | EP0733069B1 Purified primate ctla-8 antigens and related reagents |
| 03/15/2006 | CN1748029A Oligomeric compounds for the modulation of survivin expression |
| 03/15/2006 | CN1747984A Polymer guanidine derivatives as a cytostatic medicament |
| 03/15/2006 | CN1747967A Peptide conjugate |
| 03/15/2006 | CN1747965A Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 03/15/2006 | CN1747964A Medicament for inhibiting tumour growth |
| 03/15/2006 | CN1747962A Compound, process for producing the same and use thereof |
| 03/15/2006 | CN1747956A 6-substituted imidazopyrazines |
| 03/15/2006 | CN1747955A Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments |
| 03/15/2006 | CN1747953A Aryl / hetaryl substituted imidazoquinolines. |
| 03/15/2006 | CN1747952A Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| 03/15/2006 | CN1747951A Novel 2-pyridinecarboxamide derivatives |
| 03/15/2006 | CN1747950A 2-(1h-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
| 03/15/2006 | CN1747949A Acyclic pyrazole compounds |
| 03/15/2006 | CN1747948A Novel n-monoacylated o-phenylenediamines, their condensed heterocyclic derivatives and their use as pharmaceutical agents |
| 03/15/2006 | CN1747947A A process for preparing duloxetine and intermediates for use therein |
| 03/15/2006 | CN1747942A Heterocyclic compounds useful as nurr-1 activators |
| 03/15/2006 | CN1747941A HIV inhibiting 1,2,4-triazines |
| 03/15/2006 | CN1747938A Novel substituted 2,3-benzodiazepine derivatives |